Date published: 2026-4-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

HGFL α Inhibitors

HGFL α inhibitors belong to a distinct chemical class characterized by their ability to selectively modulate the activity of the hepatocyte growth factor-like (HGFL) α protein. These inhibitors are designed to interact with specific binding sites on the HGFL α protein, effectively obstructing or altering its normal biochemical functions. The chemical structure of HGFL α inhibitors is engineered to achieve a high degree of affinity and specificity for the target protein, thereby regulating its signaling pathways or physiological responses. Through their intricate molecular interactions, these inhibitors play a pivotal role in influencing cellular processes where HGFL α is involved.

The development of HGFL α inhibitors involves meticulous design and optimization to ensure optimal binding and efficacy. Researchers in this field explore the structural intricacies of both the inhibitors and the HGFL α protein to fine-tune the interaction between the two entities. This chemical class represents a sophisticated approach to manipulating cellular functions associated with HGFL α, with applications in various contexts where precise modulation of this protein's activity is desired.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

XL-184 free base

849217-68-1sc-364657
sc-364657A
5 mg
10 mg
$94.00
$208.00
1
(1)

A multi-kinase inhibitor that targets c-MET, vascular endothelial growth factor receptor (VEGFR), and rearranged during transfection (RET) kinases, among others.

ARQ 197

905854-02-6sc-364408
sc-364408A
50 mg
200 mg
$712.00
$1920.00
(0)

Originally developed as a c-MET inhibitor, Tivantinib was investigated for its potential in inhibiting HGF signaling and metastasis.

Foretinib

849217-64-7sc-364492
5 mg
$129.00
6
(1)

An investigational c-MET and VEGFR kinase inhibitor studied in research models for various cancers.

Lenvatinib

417716-92-8sc-488530
sc-488530A
sc-488530B
5 mg
25 mg
100 mg
$182.00
$661.00
$1690.00
3
(0)

While primarily known as a VEGFR inhibitor, Lenvatinib has also shown some inhibitory activity against c-MET.

Met Kinase Inhibitor

658084-23-2sc-204801
1 mg
$116.00
5
(1)

Another c-MET inhibitor that has demonstrated inhibitory effects on HGF-induced c-MET activation.